Data investigation

What Cannot Legally Be Compounded, and Who Is Selling It Anyway

Federal law bars retatrutide and cagrilintide from compounding entirely. We checked our own 560-seller register against that rule, found 7 with it on the menu, and discovered our own reviews were not telling readers.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
8 min read·1 citation

Not everything a compounding pharmacy can put in a vial is something it is allowed to put in a vial. The FDA has named specific molecules and specific chemical forms that cannot lawfully be used in compounding at all. When we checked our own register against that list in August 2026, 7 of the 560 sellers we tracked had one on their product menu.[1] Below is what the rules say, and how to check a seller against them.

Retatrutide and cagrilintide: not eligible at all

The FDA’s position is unusually blunt. Here it is in the agency’s own words:[1]

Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition.
— FDA, page current as of October 1, 2026

The last clause is stronger than people expect. Neither molecule is a diabetes drug being used off-label for weight, which describes a great deal of ordinary prescribing. Neither is approved for anything: there is no indication, anywhere, for which either molecule is an approved treatment.

The agency has acted on this in three directions at once. It has warned telehealth companies for marketing unapproved drugs such as retatrutide, including marketing straight to consumers; it has warned the active-ingredient distributors selling retatrutide and other GLP-1 drugs to compounders; and it has warned outsourcing facilities for repackaging it.[1]

Retatrutide is a promising molecule in trials. That is why it sells, but it is not a reason to buy it from a telehealth storefront today. A drug still in development has no established dose, no approved label, and no finished-product manufacturing standard behind whatever arrives at your door. Our evidence summary covers what the trials have shown so far.

What we found in our own register

In August 2026 we checked all 560 sellers we tracked. Seven had retatrutide on the product menu we hold for them. The harder finding was what our own pages said about it.

Not one of those seven reviews told a reader that retatrutide cannot lawfully be compounded. Two came closest. They said the seller’s retatrutide “is compounded rather than FDA-approved, so it has not been reviewed by the agency”. That is true of every compounded product on this site, and a materially weaker statement than the one the FDA makes about this particular molecule. The other five said nothing at all.

That has been fixed where it renders. Every seller whose menu we hold now carries a specific warning naming the FDA’s position, and an automated check keeps it there. The fix took two attempts. The first pass corrected a stored field that our pages never publish, so it warned no one. It is the same discipline we describe in how to verify a seller, applied to our own pages.

A further four sellers are recorded in our verification notes as listing retatrutide, but we do not yet hold structured menu data for them, so they are not in the seven and do not yet carry the warning. We are not naming them on the strength of a note alone. They are queued for re-verification.
Some of them are invisible to a search for the word. One sells it as “MR-3”; another files it as “Sema, tirz, reta”.

This applies well beyond our register. Searching a seller’s site for a molecule name does not tell you what the seller stocks. Abbreviations and in-house code names are common in this corner of the market, and they defeat the obvious check completely.

Salt forms are a different active ingredient

The second problem is easier to miss, and we cover it at length in compounded versus brand semaglutide. In short, some compounders work from semaglutide salts rather than the base, and the FDA treats those as a different active ingredient from the one in the approved drugs, with no lawful basis for compounding that it is aware of.[1]

For a buyer, the catch is that this almost never appears on a product page. It shows up on a certificate of analysis, if you ask for one, where “sodium” or “acetate” after the drug name gives it away.

What the FDA says about each, in its own words. Source: FDA drug alert, page current as of October 1, 2026.
What you might be offeredFDA's position
Retatrutide, cagrilintideBarred from compounding by federal law; neither is an ingredient of any approved drug, and neither has an established safety and efficacy finding for any use
Semaglutide sodium, semaglutide acetateDifferent active ingredients from the approved drugs; no lawful basis for their use in compounding that the agency is aware of
Product labeled “not for human consumption” or “for research purposes”FDA has warned companies illegally selling these direct to consumers for human use, with dosing instructions
Anything that arrived warmInjectable GLP-1s require refrigeration; FDA recommends not using a product that arrives warm or under-iced

The research-use label is not a loophole

A whole gray market runs on vials marked “not for human consumption” or “for research purposes”. The FDA has warned companies that sold these products (containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide) directly to consumers for human use, complete with dosing instructions.[1]

The wording on the label is a legal posture. It describes neither the product nor what the seller expects you to do with it. What you have is a substance of unknown quality, and no one is accountable for what is in it.

How to check a seller in five minutes

  1. Read the full product menu, not the GLP-1 page. The molecule that cannot be compounded is rarely on the page you landed on; it is usually under peptides, add-ons, or a members-only list.
  2. Watch for abbreviations and code names. “Reta”, “triple agonist”, “MR-3” and similar all point at the same molecule and none of them match a search for it.
  3. Ask what chemical form the semaglutide is. Base, or a salt. If the answer names sodium or acetate, that is the form the FDA has named.
  4. Check who compounded it. FDA has seen labels naming pharmacies that do not exist, and labels naming real pharmacies that did not make the product.[1]
  5. Look at the shipment when it lands. Warm box, melted or missing ice packs: FDA’s advice is not to use it.[1]

The fourth check is the quickest to run, and sellers answer it very differently. Onyx Weight Loss names Strive Pharmacy as its pharmacy partner, and Youth & Soul names ProCompounding Pharmacy and The Pharmacy Hub, so there is a name to look up. Youth & Soul’s plan page also calls its compounded drugs FDA-approved, which they are not. Always Wellness and Recovery says a licensed 503A pharmacy dispenses without naming it.

TRT Kingdom names the medical group that prescribes but not the pharmacy, and EmbraceRX names its physician network, Samaritan MD, while saying only that state-licensed 503A pharmacies fill. Nava Health sidesteps the question for its weight program, which pairs FDA-approved GLP-1s with lab work and nutrition coaching. Collective names neither the compounding pharmacies nor the medical groups behind its compounded semaglutide and tirzepatide anywhere in its Terms of Use.

None of this is an argument against compounded medicine as such. A compounded drug can be appropriate when a patient’s need cannot be met by an approved product, filled on a prescription at a state-licensed pharmacy.[1] The rule here is narrower: some ingredients are not eligible for that route at all.

Frequently Asked Questions

No. Federal law bars both retatrutide and cagrilintide from being compounded, and the FDA adds that neither is an ingredient of any approved drug and neither has an established safety and efficacy finding for any use. The agency has warned telehealth sellers, ingredient distributors and outsourcing facilities over it.
Not by searching for the name. Among the sellers in our register that offer it, some are invisible to that search. One sells it as 'MR-3', another files it as 'Sema, tirz, reta'. Read the whole product menu, including peptides and add-ons, and treat abbreviations as the same thing.
The FDA's position is that these salts are not the active ingredient found in the approved drugs, that it lacks information showing they act alike, and that it knows of no lawful basis for compounding with them. The distinction rarely appears on a product page; it shows up on a certificate of analysis.
No. FDA has warned companies that sold products labeled that way, or 'not for human consumption', directly to consumers for human use along with dosing instructions. The label is a legal posture rather than a description of the product.
No. A compounded drug can be appropriate when an approved product cannot meet a patient's need, prescribed by a clinician and filled at a state-licensed pharmacy. This article is about specific ingredients that are not eligible for compounding at all, which is a narrower rule.

References

  1. 1.U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — drug alert, content current as of October 1, 2026 FDA. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

Is the Vial You Received What the Label Says?

FDA has found labels naming compounding pharmacies that do not exist, and labels naming real pharmacies that did not make the product. What to check when the box arrives, and what the 990 adverse event reports mean.

8 min read

CJC-1295 and Ipamorelin: What FDA Recorded

Sold as a stack for fat loss. FDA identified serious adverse events with CJC-1295 (increased heart rate and systemic vasodilatory reaction), and neither peptide has a weight-loss trial.

7 min read

What Makes a Telehealth GLP-1 Prescription Legitimate

The FDA publishes seven warning signs for telehealth medicine sellers. Here they are, with what proper prescribing looks like and the one disclosure that 139 of our 560 sellers failed in an August 2026 count.

7 min read

BPC-157 FDA Status: What the Agency Put on the Record

Not approved, and not on the list of substances a 503A compounding pharmacy may use. FDA recorded specific concerns: immunogenicity, peptide impurities, and “no, or only limited, safety-related information”.

8 min read

What the FDA's GLP-1 Warning Letters Say About This Market

Two letters in 2023, ten in 2024, 72 in 2025. The most common subject is unlawful sale to consumers: enforcement here is overwhelmingly about what sellers said, not what pharmacies made.

6 min read

HCG, B12 and Lipotropic Shots: What the Labels and the FDA Say

HCG's own FDA-approved labeling states there is no substantial evidence it increases weight loss beyond caloric restriction. The 500-calorie diet it is sold with is the part that works, and the part that is dangerous.

6 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

7.3

Found

People who want clinician visits billed to commercial insurance, with compounded medication in the plan price

From $149/mo + membership

Get started →
Read full review →
8.5

Gala

Moving between compounded and brand without changing seller

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →